[Experimental study on 5-FU intraperitoneal injection for liver metastasis]

Area of Science:

• Pharmacokinetics
• Drug Delivery Systems
• Oncology

Context:

• Understanding 5-fluorouracil (5-FU) pharmacokinetics is crucial for optimizing cancer chemotherapy.
• Investigating alternative administration routes for 5-FU can improve therapeutic efficacy and reduce systemic toxicity.
• Liver metastasis remains a significant challenge in cancer treatment, necessitating novel drug delivery strategies.

Purpose:

• To compare 5-fluorouracil (5-FU) concentrations in peripheral and portal blood following administration via subphrenic, Douglas, or intravenous routes in rats.
• To evaluate the pharmacokinetic differences between intraperitoneal and intravenous 5-FU administration.
• To explore the potential of intraperitoneal 5-FU for treating liver metastasis based on observed blood concentration profiles.

Summary:

• Rats received 1 ml of 5-FU (250 mg/kg) via subphrenic, Douglas, or intravenous routes.
• Intraperitoneal administration (subphrenic + Douglas) yielded lower peripheral and higher portal 5-FU concentrations versus intravenous.
• Subphrenic injection resulted in significantly higher peripheral 5-FU than Douglas injection, indicating a potential alternative absorption route.

Impact:

• Findings suggest intraperitoneal 5-FU may be a viable therapeutic strategy for liver metastasis.
• The study highlights the importance of considering injection site and absorption routes for 5-FU delivery.
• Careful attention to injection site, concentration, and volume is recommended for intraperitoneal 5-FU administration.